Early warning system developed for avian influenza
21 June, 2005 by Graeme O'NeillVictorian Primary Industry researchers have developed a real-time polymerase chain reaction (PCR) test that will become the basis of an early-warning system for avian influenza.
In brief: Acrux, CyGenics, Iatia, Psivida
20 June, 2005 by Susan WilliamsonAcrux [ASX: ACR] has announced positive results for a Phase 1 proof-of-concept, pharmacokinetic study of its contraceptive spray Nesterone MDTS.
Mayne Group to demerge with new chairmen
17 June, 2005 by Susan WilliamsonAustralian healthcare company, Mayne Group, will proceed with the demerger of its global injectable pharmaceutical business, Mayne Pharma, and its domestic healthcare businesses, Mayne Diagnostic Services, Mayne Pharmacy, and Mayne Consumer Products.
New diagnostic for airborne allergens
17 June, 2005 by Graeme O'NeillA new technique that better identifies asthma and allergy triggers may soon provide some welcome relief to susceptible individuals.
Discovery time recommended in dispute between Ventracor and Heartware
17 June, 2005 by Ruth BeranAn initial recommendation has been made in the patent infringement dispute between Sydney artificial heart firms Ventracor (ASX:VCR) and Heartware (ASX:HTW).
Prana CEO resigns, PBT-2 development to continue
16 June, 2005 by Ruth BeranDr Jonas Alsenas has resigned as CEO and director of Melbourne based Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), with Geoffrey Kempler re-assuming the joint positions of executive chairman and CEO.
In brief: Psiron, pSivida, Meditech Research, Optiscan Imaging
16 June, 2005 by Ruth BeranGreg Williams is Psiron's (ASC:PSX) new chief financial officer, a position he commenced on June 14.
New insights into treating heart attack and stroke
16 June, 2005 by Susan WilliamsonAssoc Prof Shaun Jackson, from the Australian Centre for Blood Diseases at Monash University, has won this year's Amgen Medical Research Award for the discovery and development of a new treatment for coronary heart disease and stroke.
Apollo Life Sciences IPO oversubscribed and closes early
16 June, 2005 by Ruth BeranSydney-based biopharma Apollo Life Sciences has closed its AUD$9.5 million initial public offering early and heavily oversubscribed, its underwriter Blackwood Capital said.
In brief: Mesoblast, Epitan, Acrux, Avantogen
15 June, 2005 by Ruth BeranMesoblast (ASX:MSB) has appointed Dr Tamara Lewis as manager of clinical and regulatory affairs.
Opara calls for changes at Polartechnics
15 June, 2005 by Ruth BeranJust under a week since Richard Opara stepped down from his role as interim chairman of Polartechnics (ASX:PLT) and resigned as director on June 8, his company Patonville, has served a requisition on Polartechnics to convene an Extraordinary General Meeting.
Patent granted for Solbec's Cormasine
15 June, 2005 by Ruth BeranPerth biotech Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent covering aspects of the manufacturing, purification process and formulation of the active pharmaceutical ingredients of the company's lead compound Coramsine.
Metabolic raises $10 million
14 June, 2005 by Ruth BeranMelbourne based Metabolic Pharmaceuticals (ASX:MBP) has lifted its trading halt and reinstated its shares on the ASX's official quotation following the completion of a AUD$10 million private placement and the offer of a $10 million share purchase plan.
Metabolic shares suspended
10 June, 2005 by Ruth BeranMelbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
In brief: C3, GTG, Avantogen, Alchemia
09 June, 2005 by Ruth BeranClinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK.
